A systematic review and meta-analysis of the COVID-19 associated liver injury #MMPMID32882393
Wong YJ; Tan M; Zheng Q; Li JW; Kumar R; Fock KM; Teo EK; Ang TL
Ann Hepatol 2020[Nov]; 19 (6): 627-634 PMID32882393show ga
INTRODUCTION AND OBJECTIVES: The novel coronavirus disease 2019 (COVID-19) has affected more than 5 million people globally. Data on the prevalence and degree of COVID-19 associated liver injury among patients with COVID-19 remain limited. We conducted a systematic review and meta-analysis to assess the prevalence and degree of liver injury between patients with severe and non-severe COVID-19. METHODS: We performed a systematic search of three electronic databases (PubMed/MEDLINE, EMBASE and Cochrane Library), from inception to 24(th) April 2020. We included all adult human studies (>20 subjects) regardless of language, region or publication date or status. We assessed the pooled odds ratio (OR), mean difference (MD) and 95% confidence interval (95%CI) using the random-effects model. RESULTS: Among 1543 citations, there were 24 studies (5961 subjects) which fulfilled our inclusion criteria. The pooled odds ratio for elevated ALT (OR?=?2.5, 95%CI: 1.6-3.7, I(2)?=?57%), AST (OR?=?3.4, 95%CI: 2.3-5.0, I(2)?=?56%), hyperbilirubinemia (OR?=?1.7, 95%CI: 1.2-2.5, I(2)?=?0%) and hypoalbuminemia (OR?=?7.1, 95%CI: 2.1-24.1, I(2)?=?71%) were higher subjects in critical COVID-19. CONCLUSION: COVID-19 associated liver injury is more common in severe COVID-19 than non-severe COVID-19. Physicians should be aware of possible progression to severe disease in subjects with COVID-19-associated liver injury.
free
free
free
Ann+Hepatol 2020 ; 19 (6): 627-634
